



## **Prof. Kazarian Receives Volwiler Donation**

Ludwigshafen, June 21/22, 2007 - Volwiler "Outstanding Researcher Award" in 2006: In 2006 the Volwiler Society honoured their "Volwiler Research Fellow" Dr. Jörg Rosenberg of SOLIQS with the "Outstanding Researcher Award" for his outstanding scientific work in contributing to the development of SOLIQS' drug delivery technologies. His work supported the successful development of Kaletra Tablets, a unique formulation of Abbott's market-leading protease inhibitor for HIV applying MELTREX. This formulation offers a decreased pill count compared to the former soft gel capsule, improving convenience and tolerability for patients. In addition, the MELTREX tablets require no refrigeration, making the new formulation more practical for use in underdeveloped countries, where it is most needed.

### **Volwiler Donation**

The Outstanding Researcher Award is combined with a "Volwiler donation" (amounting to of 10,000 US-\$), which is intended to support internationally recognized scientific experts or institutions. This award, given annually, recognizes outstanding research conducted by a scientist in the pharmaceutical field. On the recommendation of the 2006's "Outstanding Researcher Award" winner Dr. Jörg Rosenberg, Prof. Sergei G. Kazarian was honoured as the 2006 recipient of the "Volwiler Donation".

The Volwiler Society is named after Dr. Ernest Volwiler, the scientist and former Abbott chairman whose breakthrough discoveries contributed so much to Abbott's success. Established in 1985, the society recognizes Abbott's most distinguished scientists and engineers for their creativity, scientific excellence, consistent scientific productivity, and contributions to Abbott. Abbott currently has approximately 7,000 people employed in research and development worldwide. Of these 197 are members of the Volwiler Society .

### **Biography Prof. Sergei G. Kazarian**

Sergei Kazarian is Professor of Physical Chemistry, Director of Postgraduate Studies and leads the Complex Materials Research Programme in the Department of Chemical Engineering at Imperial College London (UK). He received his diploma in physics in 1980 from the Yerevan State University (Armenia). After obtaining his PhD in Physical Chemistry from the USSR Academy of Sciences in Moscow in 1987, he moved to the Institute of Spectroscopy where he worked as a research fellow and from 1991 he held research positions in Europe (University of Nottingham, UK) and the USA (Georgia Institute of Technology, Atlanta). He joined Imperial College in 1998 and was promoted to Professor in 2006. Professor Kazarian has published over 100 articles and reviews in leading scientific journals, several book chapters and he has been an invited speaker at international conferences and research seminars in Europe, the USA, Australia and Japan. His research encompasses the fields of molecular spectroscopy, supercritical fluids, intermolecular interactions, polymeric materials and pharmaceuticals. A large part of his recent research focuses on the applications of advanced vibrational spectroscopy and spectroscopic imaging to materials, biomedical samples and pharmaceutical formulations. Professor Kazarian is a Fellow of the Royal Society of Chemistry.



Prof. Sergei G. Kazarian □  
receives Volwiler Donation□

## **Volwiler Society Honors Exceptional Abbott Scientists and Engineers**

Jörg Rosenberg, Ph.D., began his career at Abbott in 2001 through the acquisition of Knoll Pharmaceuticals. For 20 years, Dr. Rosenberg has focused his efforts on the discovery and development of new drug formulations to ensure that more therapies can benefit more patients.

Most notably, Dr. Rosenberg's outstanding scientific work in developing melt-extrusion technology, or Meltrex, and applying Meltrex® to designing novel formulations of candidate drugs, led to the successful development of Kaletra® Tablets, a novel formulation of our market-leading protease inhibitor for HIV. The new formulation offers a decreased pill count from the capsule form of the drug, improving convenience and tolerability for patients. Additionally, the tablets require no refrigeration, making the new formulation more practical for use in developing nations. Through exceptional strategic initiative and determined execution, Dr. Jörg Rosenberg supported the Kaletra team to be able to accelerate regulatory filing of Kaletra Tablets in both the United States and the European Union. Since launching the tablets in October 2005, Kaletra's U.S. market share has increased more than two share points.

Dr. Rosenberg's achievements are founded on a broad and in-depth knowledge, understanding and experience of formulation development using new drug delivery technologies and the adaptation and transfer of new technologies to the pharmaceutical field. His efforts have led to numerous successful developments, bolstering the growth of pharmaceutical pipeline and of SOLIQS drug delivery technologies at Abbott.

Dr. Jörg Rosenberg has authored and co-authored more than 30 publications and 39 patents. He resides in Ellerstadt, Germany.

The Volwiler Society is named after Dr. Ernest Volwiler, the scientist and former Abbott chairman whose breakthrough contributions to medicine contributed so much to Abbott's success. This year marks the 70th anniversary of Dr. Volwiler and Dr. Donalee Tabern's discovery of Abbott's anesthetic agent pentothal, for which both were honored with induction in the National Inventor's Hall of Fame 50 years later, in 1986.